Current strategies in the discovery of small-molecule biomarkers for Alzheimers disease

Bioanalysis

Volumn 3, Issue 10, 2011, Pages 1121-1142

  Whiley, Luke ^a   Legido Quigley, Cristina ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; 5 HYDROXYINDOLEACETIC ACID; 6 N CARBOXYMETHYLLYSINE; 8 HYDROXYGUANINE; ALPHA TOCOPHEROL; ASCORBIC ACID; BILE ACID; BIOLOGICAL MARKER; CERAMIDE; CITRIC ACID; CREATINE; CREATININE; DEXTRO ALANINE; DEXTRO ASPARTIC ACID; FUMARIC ACID; HOMOVANILLIC ACID; INOSITOL; ISOPROSTANE; LACTIC ACID; N ACETYLASPARTIC ACID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL; PHOSPHOLIPID; PLASMALOGEN; PRASTERONE; RETINOL; SPHINGOMYELIN; UNINDEXED DRUG; URIC ACID;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CAPILLARY ELECTROCHROMATOGRAPHY; CEREBROSPINAL FLUID LEVEL; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MASS FRAGMENTOGRAPHY; METABOLITE; METABOLOMICS; MOLECULAR DIAGNOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; PHASE SEPARATION; PROCESS DEVELOPMENT; REVIEW;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; IMMUNOASSAY; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY;

EID: 79956225529     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.62     Document Type: Review

References (111)

1. Alzheimers Disease Education and Referral (ADEAR) Center. A Service of the National Institute on Aging. Alzheimers Disease Fact Sheet. NIH Publication No.: 08-6423, MD, USA (2010).
2. Querfurth HW, La Ferla FM. Mechanisms of disease Alzheimers disease. N. Engl. J. Med. 362(4), 329-344 (2010).
3. Minati L, Edginton T, Bruzzone MG, Giaccone G. Current concepts in Alzheimers disease: a multidisciplinary review. Am. J. Alzheimers Dis. 24(2), 95-121 (2009).
4. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 366(9503), 2112-2117 (2005). (Pubitemid 41797645)
5. Folstein MF, Folstein SE, Mchugh PR. Mini-mental state - practical method for grading cognitive state of patients for clinician. J. Psychiatr. Res. 12(3), 189-198 (1975).
6. Holmes C, Lovestone S. Long-term cognitive and functional decline in late onset Alzheimers disease: therapeutic implications. Age Ageing 32(2), 200-204 (2003). (Pubitemid 36372428)
7. Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol. 22(5), 245-252 (2004). (Pubitemid 38515742)
8. Urbanczyk-Wochniak E, Luedemann A, Kopka J, et al. Parallel analysis of transcript and metabolic profiles: a new approach in systems biology. EMBO Rep. 4(10), 989-993 (2003). (Pubitemid 37407468)
9. Modrego PJ, Pina MA, Fayed N, Diaz M. Changes in metabolite ratios after treatment with rivastigmine in Alzheimers disease - a nonrandomised controlled trial with magnetic resonance spectroscopy. CNS Drugs 20(10), 867-877 (2006). (Pubitemid 44484248)
10. Penner J, Rupsingh R, Smith M, Wells JL, Borrie MJ, Bartha R. Increased glutamate in the hippocampus after galantamine treatment for Alzheimers disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(1), 104-110 (2010).
11. Ikura Y, Kudo T, Tanaka T, et al. Levels of tau phosphorylation at different sites in Alzheimer disease brain. Neuroreport 9(10), 2375-2379 (1998). (Pubitemid 28338237)
12. Nourooz-Zadeh J, Liu EHC, Yhlen B, Anggard EE, Halliwell B. F-4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimers disease. J. Neurochem. 72(2), 734-740 (1999). (Pubitemid 29055237)
13. Lovell MA, Xie CS, Markesbery WR. Acrolein is increased in Alzheimers disease brain and is toxic to primary hippocampal cultures. Neurobiol. Aging 22(2), 187-194 (2001). (Pubitemid 32162967)
14. Parnetti L, Tarducci R, Presciutti O, et al. Proton magnetic resonance spectroscopy can differentiate Alzheimers disease from normal aging. Mech. Ageing Dev. 97(1), 9-14 (1997). (Pubitemid 27279860)
15. Chen JG, Charles HC, Barboriak DP, Doraiswamy PM. Magnetic resonance spectroscopy in Alzheimers disease: focus on N-acetylaspartate. Acta Neurologica Scandinavica 102, 20-26 (2000). (Pubitemid 32156166)
16. Santos JMG, Gavrila D, Antunez C, et al. Magnetic resonance spectroscopy performance for detection of dementia, Alzheimers disease and mild cognitive impairment in a community-based survey. Dement. Geriatr. Cogn. 26(1), 15-25 (2008).
17. Bibl M, Mollenhauer B, Esselmann H, et al. CSF diagnosis of Alzheimers disease and dementia with Lewy bodies. J. Neural Transm. 113(11), 1771-1778 (2006). (Pubitemid 44657673)
18. Carrette O, Demalte I, Scherl A, et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimers disease. Proteomics 3(8), 1486-1494 (2003). (Pubitemid 37048074)
19. Engelborghs S, De Vreese K, Van de Casteele T, et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol. Aging 29(8), 1143-1159 (2008). (Pubitemid 351822410)
20. Fonteh AN, Harrington RJ, Huhmer AF, Biringer RG, Riggins JN, Harrington MG. Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods. Dis. Markers 22(1-2), 39-64 (2006). (Pubitemid 41831604)
21. Itoh N, Arai H, Urakami K, et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimers disease. Ann. Neurol. 50(2), 150-156 (2001). (Pubitemid 32738138)
22. Ogundare M, Theofilopoulos S, Lockhart A, et al. Cerebrospinal fluid steroidomics: are bioactive bile acids present in brain? J. Biol. Chem. 285(7), 4666-4679 (2009).
23. Pulido R, Jimenez-Escrig A, Orensanz L, Saura-Calixto F. Study of plasma antioxidant status in Alzheimers disease. Eur. J. Neurol. 12(7), 531-535 (2005). (Pubitemid 40956810)
24. Kawarabayashi T, Shoji M. Plasma biomarkers of Alzheimers disease. Curr. Opin. Psychiatry 21(3), 260-267 (2008).
25. Hye A, Lynham S, Thambisetty M, et al. Proteome-based plasma biomarkers for Alzheimers disease. Brain 129(Pt 11), 3042-3050 (2006). (Pubitemid 44684524)
26. Kim KM, Jung BH, Paeng KJ, Kim I, Chung BC. Increased urinary F-2- isoprostanes levels in the patients with Alzheimers disease. Brain Res. Bull. 64(1), 47-51 (2004). (Pubitemid 38953468)
27. Lindner MD, Gordon DD, Miller JM, et al. Increased levels of truncated nerve growth-factor receptor in urine of mildly demented patients with Alzheimers-disease. Arch. Neurol. 50(10), 1054-1058 (1993). (Pubitemid 23301250)
28. Ghanbari H, Ghanbari K, Beheshti I, Munzar M, Vasauskas A, Averback P. Biochemical assay for AD7C-NTP in urine as an Alzheimers disease marker. J. Clin. Lab. Anal. 12(5), 285-288 (1998). (Pubitemid 28462315)
29. Zipser BD, Johanson CE, Gonzalez L, et al. Microvascular injury and blood-brain barrier leakage in Alzheimers disease. Neurobiol. Aging 28(7), 977-986 (2007). (Pubitemid 46635913)
30. Kalaria RN. The blood-brain barrier and cerebrovascular pathology in Alzheimers disease. Ann. NY Acad. Sci. 893, 113-125 (1999). (Pubitemid 30038071)
31. Zarow C, Barron E, Chui HC, Perlmutter LS. Vascular basement membrane pathology and Alzheimers disease. Ann. NY Acad. Sci. 826, 147-160 (1997). (Pubitemid 27478037)
32. Jukarainen NM, Korhonen SP, Laakso MP, et al. Quantification of H-1 NMR spectra of human cerebrospinal fluid: a protocol based on constrained total-line-shape analysis. Metabolomics 4(2), 150-160 (2008).
33. Gujar SK, Maheshwari S, Bjorkman- Burtscher I, Sundgren PC. Magnetic resonance spectroscopy. J. Neuroophthalmol. 25(3), 217-226 (2005). (Pubitemid 41306683)
34. Pettegrew JW, Panchalingam K, Hamilton RL, McClure RJ. Brain membrane phospholipid alterations in Alzheimers disease. Neurochem. Res. 26(7), 771-782 (2001). (Pubitemid 32845968)
35. Tsai G, Coyle JT. N-acetylaspartate in neuropsychiatric disorders. Prog. Neurobiol. 46(5), 531-540 (1995).
36. Mohanakrishnan P, Fowler AH, Vonsattel JP, et al. Regional metabolic alterations in Alzheimers disease: an in vitro H-1 NMR study of the hippocampus and cerebellum. J. Gerontol. A Biol. Sci. Med. Sci. 52(2), B111-B117 (1997). (Pubitemid 27123961)
37. Shonk TK, Moats RA, Gifford P, et al. Probable Alzheimer-disease - diagnosis with proton Mr Spectroscopy. Radiology 195(1), 65-72 (1995).
38. Huang W, Alexander GE, Chang L, et al. Brain metabolite concentration and dementia severity in Alzheimers disease - a H-1 MRS study. Neurology 57(4), 626-632 (2001). (Pubitemid 32782989)
39. Hancu I, Zimmerman EA, Sailasuta N, Hurd RE. H-1 MR spectroscopy using TE averaged PRESS: a more sensitive technique to detect neuro degeneration associated with Alzheimers disease. Magn. Reson. Med. 53(4), 777-782 (2005). (Pubitemid 40478424)
40. Kantarci K, Jack CR, Xu YC, et al. Regional metabolic patterns in mild cognitive impairment and Alzheimers disease - a H-1 MRS study. Neurology 55(2), 210-217 (2000). (Pubitemid 30604620)
41. Block W, Jessen F, Traber F, et al. Regional N-acetylaspartate reduction in the hippocampus detected with fast proton magnetic resonance spectroscopic imaging in patients with Alzheimer disease. Arch. Neurol. 59(5), 828-834 (2002). (Pubitemid 34517767)
42. Frederick BD, Lyoo IK, Satlin A, et al. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimers disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 28(8), 1313-1322 (2004). (Pubitemid 39592929)
43. Kantarci K, Knopman DS, Dickson DW, et al. Alzheimer disease: postmortem neuropathologic correlates of antemortem H-1 MR spectroscopy metabolite measurements. Radiology 248(1), 210-220 (2008).
44. Miller BL, Moats RA, Shonk T, Ernst T, Woolley S, Ross BD. Alzheimer-disease - depiction of increased cerebral myoinositol with proton MR spectroscopy. Radiology 187(2), 433-437 (1993). (Pubitemid 23127850)
45. Martinez-Bisbal MC, Arana E, Marti- Bonmati L, Molla E, Celda B. Cognitive impairment: classification by 1H magnetic resonance spectroscopy. Eur. J. Neurol. 11(3), 187-193 (2004). (Pubitemid 38373034)
46. Han XL, Gross RW. Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics. J. Lipid Res. 44(6), 1071-1079 (2003). (Pubitemid 37279625)
47. Pratico D, Clark CM, Lee VMY, Trojanowski JQ, Rokach J, FitzGerald GA. Increased 8,12-iso-iPF(2 a)-VI in Alzheimers disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. 48(5), 809-812 (2000).
48. Pratico D, Lee VMY, Trojanowski JQ, Rokach J, Fitzgerald GA. Increased F-2-isoprostanes in Alzheimers disease: evidence for enhanced lipid peroxidation in vivo. FASEB J. 12(15), 1777-1783 (1998). (Pubitemid 28553673)
49. Kim SB, Hill M, Kwak YT, Hampl R, Jo DH, Morfin R. Neurosteroids: cerebrospinal fluid levels for Alzheimers disease and vascular dementia diagnostics. J. Clin. Endocr. Metab. 88(11), 5199-5206 (2003). (Pubitemid 37452716)
50. Volkel W, Sicilia T, Pahler A, et al. Increased brain levels of 4-hydroxy-2-nonenal glutathione conjugates in severe Alzheimers disease. Neurochem. Int. 48(8), 679-686 (2006).
51. Bohnstedt KC, Karlberg B, Wahlund LO, Jonhagen ME, Basun H, Schmidt S. Determination of isoprostanes in urine samples from Alzheimer patients using porous graphitic carbon liquid chromatography- tandem mass spectrometry. J. Chromatogr. B 796(1), 11-19 (2003). (Pubitemid 38352705)
52. Han XL, Holtzman DM, McKeel DW. Plasmalogen deficiency in early Alzheimers disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J. Neurochem. 77(4), 1168-1180 (2001). (Pubitemid 32467071)
53. Sun GY. Phospholipids and Acyl groups in subcellular-fractions from human cerebral-cortex. J. Lipid Res. 14(6), 656-663 (1973).
54. Vos JP, Lopescardozo M, Gadella BM. Metabolic and functional-aspects of sulfogalactolipids. Biochim. Biophys. Acta 1211(2), 125-149 (1994).
55. Han XL, Holtzman DM, McKeel DW, Kelley J, Morris JC. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimers disease: potential role in disease pathogenesis. J. Neurochem. 82(4), 809-818 (2002).
56. Churchwell MI, Twaddle NC, Meeker LR, Doerge DR. Improving LC-MS sensitivity through increases in chromatographic performance: comparisons of UPLC-ES- MS/MS to HPLC-ES-MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 825(2), 134-143 (2005). (Pubitemid 41423596)
57. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur. J. Pharmacol. 490(1-3), 115-125 (2004). (Pubitemid 38482165)
58. Hoyer S. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp. Gerontol. 35(9-10), 1363-1372 (2000).
59. Beal MF. Energy, oxidative damage, and Alzheimers-disease - clues to the underlying puzzle. Neurobiol. Aging 15, S171-S174 (1994).
60. Redjems-Bennani N, Jeandel C, Lefebvre E, Blain H, Vidailhet M, Gueant JL. Abnormal substrate levels that depend upon mitochondrial function in cerebrospinal fluid from Alzheimer patients. Gerontology 44(5), 300-304 (1998). (Pubitemid 28403393)
61. Zhu X, Lee HG, Casadesus G, et al. Oxidative imbalance in Alzheimers disease. Mol. Neurobiol. 31(1-3), 205-217 (2005).
62. Christen Y. Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr. 71(2), 621S-629S (2000). (Pubitemid 30061247)
63. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ. Cerebrospinal fluid F-2- isoprostane levels are increased in Alzheimers disease. Ann. Neurol. 44(3), 410-413 (1998). (Pubitemid 28421451)
64. Montine TJ, Beal MF, Cudkowicz ME, et al. Increased CSF F-2-isoprostane concentration in probable AD. Neurology 52(3), 562-565 (1999). (Pubitemid 29075604)
65. Montine TJ, Sidell KR, Crews BC, et al. Elevated CSF prostaglandin E-2 levels in patients with probable AD. Neurology 53(7), 1495-1498 (1999). (Pubitemid 29491943)
66. Montine TJ, Kaye JA, Montine KS, McFarland L, Morrow JD, Quinn JF. Cerebrospinal fluid Ab(42), tau, and F-2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Arch. Pathol. Lab. Med. 125(4), 510-512 (2001). (Pubitemid 32291556)
67. Quinn JF, Montine KS, Moore M, Morrow JD, Kaye JA, Montine TJ. Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimers disease. J. Alzheimers Dis. 6(1), 93-97 (2004). (Pubitemid 38418561)
68. Yoshida Y, Yoshikawa A, Kinumi T, et al. Hydroxyoctadecadienoic acid and oxidatively modified peroxiredoxins in the blood of Alzheimers disease patients and their potential as biomarkers. Neurobiol. Aging 30(2), 174-185 (2009).
69. Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimers disease. J. Neurochem. 93(4), 953-962 (2005). (Pubitemid 40695754)
70. Brown RC, Han ZQ, Cascio C, Papadopoulos V. Oxidative stress-mediated DHEA formation in Alzheimers disease pathology. Neurobiol. Aging 24(1), 57-65 (2003). (Pubitemid 36001985)
71. Attal-Khemis S, Dalmeyda V, Michot JL, Roudier M, Morfin R. Increased total 7 a-hydroxy-dehydroepiandrosterone in serum of patients with Alzheimers disease. J. Gerontol. A Biol. Sci. Med. Sci. 53(2), B125-B132 (1998). (Pubitemid 28136140)
72. Fan J, Donkin J, Wellington C. Greasing the wheels of Ab clearance in Alzheimers disease: the role of lipids and apolipoprotein E. BioFactors 35(3), 239-248 (2009).
73. Ahmed N, Ahmed U, Thornalley PJ, Hager K, Fleischer G, Munch G. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimers disease and link to cognitive impairment. J. Neurochem. 92(2), 255-263 (2005). (Pubitemid 40194017)
74. Gackowski D, Rozalski R, Siomek A, et al. Oxidative stress and oxidative DNA damage is characteristic for mixed Alzheimer disease/ vascular dementia. J. Neurol. Sci. 266(1-2), 57-62 (2008). (Pubitemid 351186523)
75. Rinaldi P, Polidori MC, Metastasio A, et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimers disease. Neurobiol. Aging 24(7), 915-919 (2003). (Pubitemid 36962976)
76. Wang W, Shinto L, Connor WE, Quinn JF. Nutritional biomarkers in Alzheimers disease: the association between carotenoids, n-3 fatty acids, and dementia severity. J. Alzheimers Dis. 13(1), 31-38 (2008). (Pubitemid 351365625)
77. Sjögren M, Minthon L, Passant U, Blennow K, Wallin A. Decreased monoamine metabolites in frontotemporal dementia and Alzheimers disease. Neurobiol. Aging 19(5), 379-384 (1998). (Pubitemid 29065486)
78. Marcelis M, Suckling J, Hofman P, Woodruff P, Bullmore E, van Os J. Evidence that brain tissue volumes are associated with HVA reactivity to metabolic stress in schizophrenia. Schizophr. Res. 86(1-3), 45-53 (2006). (Pubitemid 44251276)
79. Walter A, Korth U, Hilgert M, et al. Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients. Neurobiol. Aging 25(10), 1299-1303 (2004). (Pubitemid 39299166)
80. Wittke S, Mischak H, Walden M, Kolch W, Radler T, Wiedemann K. Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: towards new diagnostic and therapeutic approaches. Electrophoresis 26(7-8), 1476-1487 (2005). (Pubitemid 40645466)
81. Verpillot R, Otto M, Klafki H, Taverna M. Simultaneous analysis by capillary electrophoresis of five amyloid peptides as potential biomarkers of Alzheimers disease. J. Chromatogr. A 1214(1-2), 157-164 (2008).
82. Colombo R, Carotti A, Catto M, et al. CE can identify small molecules that selectively target soluble oligomers of amyloid b protein and display antifibrillogenic activity. Electrophoresis 30(8), 1418-1429 (2009).
83. Thorsen G, Bergquist J. Chiral separation of amino acids in biological fluids by micellar electrokinetic chromatography with laser-induced fluorescence detection. J. Chromatogr. B 745(2), 389-397 (2000). (Pubitemid 30665563)
84. Fisher GH, Daniello A, Vetere A, Padula L, Cusano GP, Man EH. Free d-aspartate and d-alanine in normal and Alzheimer brain. Brain Res. Bull. 26(6), 983-985 (1991).
85. Hiraoka A, Arato T, Tominaga I. Capillary zone electrophoretic determination of 5-hydroxy-indoleacetic acid and homovanillic acid in cerebrospinal fluid from patients with neuropsychiatric disorders. Jpn. J. Electrophor. 40(4), 193-197 (1996).
86. Tenorio-Lopez FA, del Valle-Mondragon L, Martinez-Lazcano JC, et al. CZE determination of quinolinic acid in rat brain tissue and plasma. Chromatographia 65(11-12), 725-731 (2007). (Pubitemid 46883634)
87. Santamaria A, Rios C. Mk-801, an N-methyl-d-aspartate receptor antagonist, blocks quinolinic acid-induced lipid-peroxidation in rat corpus striatum. Neurosci. Lett. 159(1-2), 51-54 (1993). (Pubitemid 23283236)
88. Leipnitz G, Schumacher C, Scussiato K, et al. Quinolinic acid reduces the antioxidant defenses in cerebral cortex of young rats. Int. J. Dev. Neurosci. 23(8), 695-701 (2005). (Pubitemid 41674508)
89. Vamos E, Pardutz A, Klivenyi P, Toldi J, Vecsei L. The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection. J. Neurol. Sci. 283(1-2), 21-27 (2009).
90. Guillemin GJ, Brew BJ. Implications of the kynurenine pathway and quinolinic acid in Alzheimers disease. Redox Rep. 7(4), 199-206 (2002).
91. Feillet-Coudray C, Tourtauchaux R, Niculescu M, et al. Plasma levels of 8-epiPGF2 [a], an in vivo marker of oxidative stress, are not affected by aging or Alzheimers disease. Free Radical Bio. Med. 27(3-4), 463-469 (1999). (Pubitemid 29395442)
92. Armanini D, Vecchio F, Basso A, et al. Alzheimers disease. Endocrine 22(2), 113-118 (2003).
93. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimers disease. J. Neurosci. 17(8), 2653-2657 (1997). (Pubitemid 27154998)
94. Nicholson JK, Lindon JC. Systems biology - metabonomics. Nature 455(7216), 1054-1056 (2008).
95. Greenberg N, Grassano A, Thambisetty M, Lovestone S, Legido-Quigley C. A proposed metabolic strategy for monitoring disease progression in Alzheimers disease. Electrophoresis 30(7), 1235-1239 (2009).
96. Madsen R, Lundstedt T, Trygg J. Chemometrics in metabolomics - a review in human disease diagnosis. Anal. Chim. Acta 659(1-2), 23-33 (2010).
97. Brindle JT, Antti H, Holmes E, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat. Med. 8(12), 1439-1444 (2002). (Pubitemid 36019430)
98. Lindon JC, Holmes E, Nicholson JK. Metabonomics in pharmaceutical R&D. FEBS J. 274(5), 1140-1151 (2007).
99. Holmes E, Loo RL, Stamler J, et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 453(7193), 396-400 (2008). (Pubitemid 351693125)
100. Tsang TM, Huang JTJ, Holmes E, Bahn S. Metabolic profiling of plasma from discordant schizophrenia twins: correlation between lipid signals and global functioning in female schizophrenia patients. J. Proteome Res. 5(4), 756-760 (2006).
101. Holmes E, Tsang TM, Huang JTJ, et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 3(8), e327 (2006).
102. Lan MJ, McLoughlin GA, Griffin JL, et al. Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder. Mol. Psychiatry 14, 269-279 (2008).
103. Ghauri FYK, Nicholson JK, Sweatman BC, et al. NMR-spectroscopy of human postmortem cerebrospinal-fluid - distinction of Alzheimers-disease from control using pattern-recognition and statistics. NMR Biomed. 6(2), 163-167 (1993).
104. Tukiainen T, Tynkkynen T, Makinen VP, et al. A multimetabolite analysis of serum by H-1 NMR spectroscopy: early systemic signs of Alzheimers disease. Biochem. Bioph. Res. Co. 375(3), 356-361 (2008).
105. Modrego PJ, Fayed N, Pina MA. Conversion from mild cognitive impairment to probable Alzheimers disease predicted by brain magnetic resonance spectroscopy. Am. J. Psychiatry, 162(4), 667-675 (2005). (Pubitemid 40489127)
106. Salek RM, Xia J, Innes A, et al. A metabolomic study of the CRND8 transgenic mouse model of Alzheimers disease. Neurochem. Int. 56(8), 937-947 (2010).
107. Wang D-C, Sun C-H, Liu L-Y, et al. Serum fatty acid profiles using GC-MS and multivariate statistical analysis: potential biomarkers of Alzheimers disease. Neurobiol. Aging DOI: 10.1016/j.neurobiolaging.2010. 09.013 (2010) (Epub ahead of print).
108. Thambisetty M, Simmons A, Velayudhan L, et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch. Gen. Psychiatry 67(7), 739-748 (2010).
109. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimers disease. Nat. Genet. 41(10), 1088-1093 (2009).
110. Rosenling T, Slim CL, Christin C, et al. The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF). J. Proteome Res. 8(12), 5511-5522 (2009).
111. What is Alzheimers Disease? Alzheimers Society (2008). http://alzheimers.org.uk/site/scripts/ documents-info.php?documentID=100